Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,650.50
Bid: 1,650.00
Ask: 1,651.00
Change: -0.50 (-0.03%)
Spread: 1.00 (0.061%)
Open: 1,656.50
High: 1,661.50
Low: 1,650.00
Prev. Close: 1,651.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

3 Feb 2014 10:46

Glaxo Gets FDA Breakthrough Therapy Label For Bone Marrow Treatment

LONDON (Alliance News) - GlaxoSmithKline PLC said Monday that it had received Breakthrough Therapy designation for its bone marrow disorder treatment Promacta/Revolade from the US Food and Drug Administration. The treatment is designed for patients with severe aplastic anemia, a rare disord

Read more
3 Feb 2014 07:54

PRESS: Glaxo To Announce Late Stage Trials On 10 New Drugs - The Telegraph

LONDON (Alliance News) - GlaxoSmithKline PLC will this week announce plans to launch late stage clinical trials on ten new drugs over the next two years, the Daily Telegraph reported Monday, without saying where it got the information. The list will include medicines in Glaxo?s key areas of

Read more
3 Feb 2014 00:32

GSK to launch late-stage clinical trials on 10 new drugs -paper

Feb 3 (Reuters) - GlaxoSmithKline is set to unveil plans to launch late-stage clinical trials on 10 new drugs over the next two years, the Telegraph reported, without citing sources. The new drugs, which have not been detailed to investors, will include cancer and respiratory disease medici

Read more
2 Feb 2014 17:27

Sunday newspaper round-up: RBS, Centrica, Vodafone

The Bank of England will question Royal Bank of Scotland over its capital position in the next two weeks, the Sunday Telegraph reported. The BoE's Prudential Regulatory Authority arm will call in RBS boss Ross McEwan to check on the bank's capital strength in light of his strategy review, due Februa

Read more
31 Jan 2014 18:58

Merck gets buyout interest for consumer health unit -sources

By Soyoung Kim and Olivia Oran NEW YORK, Jan 31 (Reuters) - Merck & Co Inc has received approaches from large consumer companies interested in buying its consumer healthcare business, best known for Coppertone sunscreen and Claritin allergy medicine, according to people familiar with the ma

Read more
31 Jan 2014 16:07

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
31 Jan 2014 14:48

Euro zone stocks to outshine Britain's FTSE if economy recovers

* Global economy on road to recovery * Germany, Spain, Italy indexes have big cyclical exposure * UK's FTSE laden with defensives, low beta energy stocks By Tricia Wright LONDON, Jan 31 (Reuters) - The global economy is on the mend, and for equity investors betting on a re

Read more
31 Jan 2014 09:00

Sinclair IS Pharma Acquires Wrinkle Treatment Atlean From Glaxo

LONDON (Alliance News) - Sinclair IS Pharma PLC said Friday that it had acquired dermal filler Atlean from GlaxoSmithKline PLC's dermatology business Stiefel. The company said that Atlean, used to reduce wrinkles, will complement its existing facial care brands Sculptra and Perfectha. Atlea

Read more
31 Jan 2014 06:26

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
30 Jan 2014 16:13

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
30 Jan 2014 06:29

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
30 Jan 2014 05:01

J&J chooses Yale to review requests for clinical drug data

Jan 30 (Reuters) - Johnson & Johnson has selected the Yale School of Medicine to review requests from investigators and physicians looking for access to clinical trial data involving the diversified healthcare company's pharmaceuticals. Under the agreement, the "Yale Open Data Access Projec

Read more
29 Jan 2014 16:33

UK Earnings, Trading Statements Calendar - Week Ahead

Read more
29 Jan 2014 09:54

UPDATE 2-Novartis weighs joint ventures, unconventional deals for smaller businesses

* Q4 sales $15.08 bln vs poll average of $15.09 bln * Core EPS $1.20 vs $1.28 forecast in Reuters poll * Expects 2014 sales to grow in the low to mid-single digits * CEO wants portfolio review complete by summer * Proposes dividend of 2.45 Sfr per share, up 7 pct By

Read more
28 Jan 2014 12:25

UPDATE 1-Production snag forces worldwide hold on GSK chickenpox vaccines

* Release of Priorix-Tetra, Varilrix put on temporary hold * Follows quality issue with some batches made in Belgium * German doctors told to ration both chickenpox vaccines FRANKFURT/LONDON, Jan 28 (Reuters) - GlaxoSmithKline has stopped worldwide deliveries of two chickenpox

Read more

Quickpicks are a member only feature

Login to your account